BBIO vs DASH · rev $221.9M vs P/E 76, rev $13.72B
BridgeBio Pharma Inc (BBIO) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
BBIO currently screens at market cap $13.24B. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the BBIO and DASH stock pages for the full models.
Not investment advice.